Quizartinib

(Vanflyta®)

Quizartinib

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormTablet (oral; 17.7 mg, 26.5 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients newly diagnosed with acute myeloid leukemia that meets certain criteria (FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Quizartinib (Vanflyta) is indicated for use in combination with standard cytarabine and anthracycline induction, cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy. It is used to treat adult patients newly diagnosed with acute myeloid leukemia that meets certain criteria (FLT3 internal tandem duplication positive).
  • Two studies compared the effectiveness and safety of Vanflyta against other FLT3 inhibitors like midostaurin and gilteritinib in treating acute myeloid leukemia.
  • The studies suggest that while FLT3 inhibitors have challenges, such as resistance, toxicities, and drug interactions, they are generally well tolerated compared to traditional chemotherapy and newer immunotherapies. This highlights their importance in the management of both fit and unfit AML patients.
  • According to one study, the clinical effectiveness of FLT3 inhibitors showed a favorable impact on survival outcomes, including an overall survival hazard ratio of 0.83, indicating potential improvement in event-free and relapse-free survival rates.
  • Despite their effectiveness, FLT3 inhibitors are associated with a higher risk of grade 3 or above adverse events, including vascular complications, dermatological issues, respiratory problems, and hepatobiliary complications. However, the actual numbers were relatively small, emphasizing the need for vigilant monitoring and comparative analysis between each inhibitor to find the most suitable option with the least adverse effects for the individual patient.
  • One study pointed out ongoing trials targeting older patients, highlighting the necessity to assess the optimum use of these drugs across different patient characteristics and disease stages. This suggests a gap in current data, especially for specific subgroups such as older patients, underscoring the need for future research to tailor treatment approaches more effectively.